Option chain shows key data for Talis Biomedical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Talis Biomedical.

Talis Biomedical (OTC:TLIS) Stock, Option Chain

Talis Biomedical

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIXI

ATXI

DPRO

ELAB

GLPG

MIRA

OKYO

PMNT

RNLX

SPRC

STEC

SVMH

TCJH

TLIS

TRSG

TVGN

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Wall Street

Earnings

Equities

Eurozone

Commodities

Intraday Update

GTHX

PETQ

STEM

UPST

XPON

Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast

oil ai

Crude Oil Jumps Over 3%; Upstart Shares Spike Higher

TALIS BIOMEDICAL CORP by Talis Biomedical Corporation

Talis Biomedical Corp

Needham analyst Tom Nikic initiates coverage on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a Buy rating and announces Price Target of $116.

Price Target

Initiation

Analyst Ratings

CROX

Needham Initiates Coverage On Crocs with Buy Rating, Announces Price Target of $116

Needham analyst Tom Nikic initiates coverage on Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Hold rating.

SHOO

Needham Initiates Coverage On Steven Madden with Hold Rating

U.S. stocks could open on a negative note on Friday after futures showed tentativeness on Friday. Investors turned their focus to cyclical stocks and themes, moving on from their <a href="https://www.benzinga.com/24/11/42058223/us-stocks-likely-to-open-in-red-as-geopolitical-tension-weigh-on-investor-sentiment-wharton-economist-says-market-trajectory-will-heavily-depend-on-trumps-tariff-plans">focus on the Trump trade</a> after the election results.
Futures of the three major indices were mixed, with the Nasdaq heading lower after AI giant Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) posted its highly-anticipated third-quarter results.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.51%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.29%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.08%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged lower by 0.34% to $591.68 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.39% to $503.03, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Thursday in the green, with the Dow Jones surging by over 450 points, while the tech-heavy Nasdaq registered marginal gains.
Crude oil futures continued on their upward trajectory amid rising tensions between Russia and Ukraine.
Treasury yields eased marginally on mixed data and the declining probability of the Federal Open Market Committee (FOMC) cutting interest rates in December.
On the economic data front, U.S. existing home sales gained 3.5% from the previous month to an annualized rate of 3.96 million in October. The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8.
Initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, financials, and consumer staples stocks recording the biggest gains on Thursday.
However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.03%</td>
<td>18,972.42</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.53%</td>
<td>5,948.71</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.06%</td>
<td>43,870.35</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.65%</td>
<td>2,364.02</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Powell's relatively hawkish tone has investors cautious in the markets. With the Trump trade losing steam, the focus is now on the President-elect's Treasury pick.
"In focus currently is President-elect Trump's pick for the influential post of US Treasury Secretary. Given the large US budget deficit, investors will probably want to see a safe pair of hands being chosen," ING analysts said in a note.
With the next rate cut now a coin toss, the U.S. dollar could see a correction. According to ING analyst Francesco Pesole, the dollar is "testing the limit" of its longs and traders should exercise caution for the time being.
"Powell seemed to put greater emphasis on the strength of the economy&nbsp;and how that allows the central bank to approach the upcoming policy decisions ‘carefully'."
CME Group's FedWatch tool <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">reflected</a> the fall in sentiment for another rate cut next month, with its probability declining to 59.6% from 72.2%.
&#8220;The case for a Fed pause in December is getting stronger and Fed officials are communicating that they are open to it going into the next meeting,&#8221; Kathy Jones, chief fixed income strategist at Schwab, said in a recent note.
&#8220;It will come down to employment and inflation data.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Friday's major economic updates include:
<ul>
<li>S&amp;P U.S. Services and Manufacturing Purchasing Manager's Index will be released at 9:45 a.m. ET.</li>
<li>Consumer sentiment data will be released at 10 a.m. ET.</li>
<li>Fed Gov. Michelle Bowman will speak at 6:15 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>The Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) stock surged 15% in premarket trading after the <a href="https://www.benzinga.com/news/earnings/24/11/42125007/gap-stock-soars-on-better-than-expected-q3-results-raised-fy-guidance-details">retailer raised its annual target</a> with a "strong" outlook for the holiday season.</li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock surged over 2% in premarket trading on Friday as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">inched closer to the $100,000 mark</a>. Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock was also up over 0.5%.</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock <a href="https://www.benzinga.com/24/11/42132644/reddit-falls-7-in-afterhours-as-advance-plans-stake-sale-technicals-show-strong-support-but-selling-pressure-persists-at-overbought-levels">fell over 7% in premarket trading</a> after the social media company amid Advance's stake sale announcement.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) stock fell over 4.7% on Thursday after the U.S. Department of Justice (DOJ) pushed forward with its demands for <a href="https://www.benzinga.com/24/11/42131274/why-googles-chrome-battle-isnt-just-about-search-gene-munster-calls-it-a-tough-day-for-big-tech-on-the-regulatory-front">Google to divest</a> the Chrome web browser.</li>
<li>Investors are awaiting earnings results from Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) and Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, surging by 0.61% to hover around $70.54 per barrel.
The 10-year Treasury note yield eased to 4.396%.
Most of the major Asian markets ended in the green on Friday, but European markets were mixed in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Economics

Federal Reserve

$BTC

DXLG

GOOG

GOOGL

HOOD

MSTR

NVDA

RDDT

US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump's Treasury Pick In Focus, Expert Says Case For Fed Pause In December 'Getting Stronger'

Needham analyst Tom Nikic initiates coverage on Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy rating and announces Price Target of $218.

DECK

Needham Initiates Coverage On Deckers Outdoor with Buy Rating, Announces Price Target of $218

Shares of Elastic N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 guidance <a href="https://www.benzinga.com/quote/ESTC/news">above estimates</a>.
Elastic reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 38 cents per share. The company reported quarterly sales of $365.361 million which beat the analyst consensus estimate of $355.900 million.
Elastic shares jumped 29.1% to $121.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 67.1% to $0.9855 in pre-market trading after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 50.4% to $1.88 in pre-market trading after dipping 62% on Thursday.</li>
<li>Beneficient  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 30.7% to $1.15 in pre-market trading after gaining around 7% on Thursday.</li>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) gained 25.4% to $1.38 in pre-market trading after declining around 75% on Wednesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 19.4% to $12.98 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) gained 14.9% to $25.33 in pre-market trading after reporting better-than-expected third-quarter results.</li>
<li>Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) gained 10.4% to $6.90 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) climbed 8.7% to $1.63 in pre-market trading.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) gained 7% to $153.01 in pre-market trading after the company reported better-than-expected third-quarter EPS results..</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares tumbled 41.8% to $10.64 in pre-market trading after the company announced the pricing of $12.1 million public offering.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 33.3% to $9.01 in pre-market trading.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 27.2% to $0.1430 in pre-market trading after the company announced its board approved a 1-for-35 reverse stock split.</li>
<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 18.7% to $0.90 in pre-market trading as the company said it faced Nasdaq delisting threat due to Form 20-F filing delay.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Real Messenger Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMSG#NASDAQ">RMSG</a>) dipped 16.2% to $3.51 in pre-market trading after jumping over 10% on Thursday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) fell 13.9% to $0.21 in pre-market trading after dipping more than 10% on Thursday.</li>
<li>Envoy Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares dipped 12.7% to $1.92 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 5.7% to $639.95 in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

AMIX

APTO

BENF

CARE

CETX

Envoy Medical, Inc. - Class A Common Stock

COCH

ESTC

INTU

KAPA

KSCP

PROC

RMSG

ROST

VRPX

XCUR

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

Needham analyst Tom Nikic initiates coverage on Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Buy rating and announces Price Target of $27.

Needham Initiates Coverage On Foot Locker with Buy Rating, Announces Price Target of $27

Needham analyst Mike Matson downgrades TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Buy to Hold and maintains the price target from $109 to $109.

Downgrades

TMDX

Needham Downgrades TransMedics Gr to Hold, Maintains Price Target to $109

Needham analyst Tom Nikic initiates coverage on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and announces Price Target of $84.

Needham Initiates Coverage On Nike with Buy Rating, Announces Price Target of $84

ZKH Group Inks Pact With With Zhejiang Tmall Technology Co. To Establish Cooperation Of GBB Platform With Zhejiang Tmall's Industrial Product Platform; Agreement Will Be Effective Until October 31

Needham analyst Tom Nikic reiterates Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Under Armour

Needham analyst Tom Nikic initiates coverage on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy rating and announces Price Target of $64.

ONON

Needham Initiates Coverage On On Holding with Buy Rating, Announces Price Target of $64

The Starship&#8216;s many engines are isolated from each other, preventing the risk of one engine failure causing failure of all as in the case of the Soviet Union&#8217;s N1 rocket, SpaceX CEO Elon Musk said on Thursday.
What Happened: &#8220;If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability,&#8221; Musk said in a post on social media platform X. &#8220;The problem with N-1 was that a failure of any engine caused failure of all.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability. The problem with N-1 was that a failure of any engine caused failure of all.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1859667589817041394?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Starship has often been compared to the Soviet N1 rocket owing to its large number of engines. Musk himself has admitted that the <a href="https://www.benzinga.com/news/23/05/32566212/elon-musk-reacts-to-comparison-of-starship-with-doomed-rocket-that-knocked-soviet-union-out-of-moon">N1 is the closest comparable rocket to Starship</a>. However, the Starship has 33 engines on its Super Heavy booster, even more than the 30 engines on the Soviet N1&#8217;s first stage.
About N1: N1 was aimed at enabling crewed travel to the moon. However, all four attempts to launch failed and the program was suspended in 1974.
The Soviets carried out a clandestine launch of the N1 on July 3, 1969, which ended up in a colossal explosion. This effectively knocked out the Soviet Union from the Moon race just days before U.S. astronauts walked on the surface of the moon.
About Starship: Starship is SpaceX&#8217;s most ambitious launch vehicle aimed at taking humans back to the Moon and Earth&#8217;s neighboring planet Mars. 
The company has conducted six test flights of the vehicle thus far but without a payload. The last flight test took place earlier this week and NASA is looking forward to taking humans back to the surface of the Moon after a gap of over 50 years with the help of a <a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs">custom version of Starship</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

General

SpaceX CEO Elon Musk Explains How Starship's Engine Design Prevents Chain Failures Unlike Soviet N1 Rocket

ZKH Group Q3 Adj EPS $(0.06), Sales $324.995M; Exits Quarter With Cash & Equivalents Worth $294.2M

Qudian (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) reported quarterly earnings of $0.10 per share. This is a 190.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported $7.80 million in sales this quarter. This is a 92.26 percent increase over sales of $4.06 million the same period last year.

Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY

JMP Securities analyst Matthew Carletti downgrades Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) from Market Outperform to Market Perform.

ROOT

JMP Securities Downgrades Root to Market Perform

Texas Governor&nbsp;Greg Abbott (R-Texas) has directed state agencies to cease investments in China and divest existing ones. This decision, announced in a letter dated Nov. 21, highlights security and financial risks associated with Chinese investments, 
What Happened: Abbott&#8217;s directive argues that this aggression could elevate the financial risks tied to Chinese investments. The governor&#8217;s letter explicitly bans Texas investing entities from making new investments in China.
Moreover, Abbott has instructed these entities to divest from any current Chinese investments at the earliest feasible opportunity. 
&#8220;Texas will defend and safeguard itself and our public treasury from any potential threat, including those posed by the CCP,&#8221; the statement read.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42103633/chinese-court-affirms-cryptocurrency-ownership-as-legal-as-bitcoin-breaks-97k?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Judge Cites &#8216;High-Pressure Crackdown&#8217; On Speculation In Judgment Declaring Crypto Ownership Legal As Bitcoin Moves Past $97K</a>
Why It Matters: The directive from Governor Abbott comes amid escalating U.S.-China tensions. Recently, the U.S. House of Representatives advanced two Republican bills aiming to reinstate the U.S. Justice Department's "China Initiative." This initiative seeks to <a href="https://www.benzinga.com/news/24/09/40831428/house-gop-advances-bills-to-reinstate-justice-departments-china-initiative-despite-white-house-disap">curb espionage activities</a> targeting U.S. intellectual property and academic institutions. The bills were part of the House Republican's &#8220;China Week,&#8221; which saw over two dozen China-related legislative measures passed.
President-elect Donald Trump has proposed to impose 60% tariff on Chinese goods. Chinese President Xi Jinping recently <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">expressed a willingness</a> to collaborate with the U.S. government, regardless of the administration in power. This statement was made during a meeting with President Joe Biden at the Asia-Pacific Economic Cooperation forum in Lima. 
Meanwhile, ETFs that allow investment into China have dropped during the past one month. As of Nov. 22nd, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) has dropped by 5.97% while iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) fell by 5.13%. Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) fell by 5.41% and iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) dropped by 5.54%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42111283/elon-musks-starlink-faces-new-competition-as-chinese-satellite-firm-spacesail-enters-brazilian-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

Government

Global

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

Texas Governor Mandates State Agencies To Divest From China: 'Will Defend And Safeguard Itself...From Any Potential Threat'

Needham analyst Quinn Bolton maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and lowers the price target from $950 to $600.

MPWR

Needham Maintains Buy on Monolithic Power Systems, Lowers Price Target to $600

Macro Economic Events

Econ #s

U.K. Services Purchasing Managers Index Preliminary For November 50.0 Vs. 52.3 Est.; 52.0 Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For November 48.6 Vs. 50.1 Est.; 49.9 Prior

U.K. Composite Purchasing Managers' Index Preliminary For November 49.9 Vs. 51.8 Prior

Talis Biomedical (TLIS) has released an update to notify the public and investors about its officers. Talis Biomedical Corporation, following its s...

Talis Biomedical Ends Role of President Amid Reorganization

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the fourth quarter of 2023.<ul><li>Talis Biomedical reported earnings per share of -$7.39.</li><li>The company reported revenue of $195,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/tlis-stock-earnings-talis-biomedical-for-q4-of-2023/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023

The latest update is out from Talis Biomedical (TLIS). Talis Biomedical Corporation has struck a retention deal with Interim CFO Rebecca Markovich,...

Talis Biomedical Secures Interim CFO Amidst Corporate Changes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the first quarter of 2024.<ul><li>Talis Biomedical reported earnings per share of -$7.15.</li><li>The company reported revenue of $73,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tlis-stock-earnings-talis-biomedical-for-q1-of-2024/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024

Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2024 Update

Talis Biomedical (TLIS) has shared an update. Talis Biomedical Corporation is undergoing significant board restructuring, which includes the resign...

Talis Biomedical Announces Board Shake-Up Amid Financial Struggles

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!



Earnings reports, an acquisition deal and more are behind today&rsquo;s biggest stock market movements.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock is rocketing 78% higher alongside heavy pre-market trading.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are soaring more than 65% on <a href="https://finance.yahoo.com/news/pharmacosmos-group-acquire-g1-therapeutics-102900391.html">an acquisition deal</a>.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is surging over 48% with strong early morning trading.</li>



<li>AlphaVest Acquisition Corp &ndash; Right (NASDAQ:<a href="https://investorplace.com/stock-quotes/atmvr-stock-quote/">ATMVR</a>) shares are gaining more than 46% this morning.</li>



<li>Inogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ingn-stock-quote/">INGN</a>) stock is increasing over 31% with its <a href="https://www.nasdaq.com/press-release/inogen-announces-second-quarter-2024-financial-results-2024-08-06">Q2 earnings report</a>.</li>



<li>Upstart (NASDAQ:<a href="https://investorplace.com/stock-quotes/upst-stock-quote/">UPST</a>) shares are rising more than 25% after <a href="https://finance.yahoo.com/news/upstart-holdings-inc-upst-reports-221010260.html">reporting a Q2 revenue beat</a>.</li>



<li>Lumen Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/lumn-stock-quote/">LUMN</a>) stock is heading over 24% higher <a href="https://www.fool.com/earnings/call-transcripts/2024/08/06/lumen-technologies-lumn-q2-2024-earnings-call-tran/">with its latest earnings</a>.</li>



<li>Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) shares are climbing close to 22% after <a href="https://www.nasdaq.com/press-release/veracyte-announces-second-quarter-2024-financial-results-2024-08-06">announcing its Q2 results</a>.</li>



<li>Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/evav-stock-quote/">EVAV</a>) are jumping more than 19% this morning.</li>



<li>Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) stock is up 18% on <a href="https://za.investing.com/news/stock-market-news/shopify-stock-soars-on-solid-q2-report-issues-q3-guidance-432SI-3275444">solid Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) shares are crashing over 79% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500722&amp;type=PDF&amp;symbol=SCPX&amp;cdn=70e2821112bdd2f31adb78fe13cd4e38&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=FWP&amp;formDescription=Filing+under+Securities+Act+Rules+163%2F433+of+free+writing+prospectuses&amp;dateFiled=2024-08-07">proposed public offering</a>.</li>



<li>Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is plummeting more than 47% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">on restructuring updates</a>.</li>



<li>DZS (NASDAQ:<a href="https://investorplace.com/stock-quotes/dzsi-stock-quote/">DZSI</a>) shares are diving over 45% as it <a href="https://www.nasdaq.com/press-release/dzs-receives-expected-delisting-notice-nasdaq-2024-08-06">prepares for a delisting notice</a>.</li>



<li>Stem (NYSE:<a href="https://investorplace.com/stock-quotes/stem-stock-quote/">STEM</a>) stock is tumbling 38% <a href="https://finance.yahoo.com/news/stem-inc-stem-reports-q2-221513320.html">on Q2 misses</a>.</li>



<li>Nevro (NYSE:<a href="https://investorplace.com/stock-quotes/nvro-stock-quote/">NVRO</a>) shares are taking a more than 37% beating after <a href="https://www.marketwatch.com/story/nevro-shares-fall-21-cuts-2024-revenue-outlook-75cf8aa9?mod=newsviewer_click">cutting its revenue outlook</a>.</li>



<li>Emergent BioSolutions (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/">EBS</a>) stock is sliding over 35% <a href="https://www.stocktitan.net/news/EBS/emergent-bio-solutions-reports-second-quarter-2024-financial-h8fhmjurwquo.html">alongside its Q2 results</a>.</li>



<li>VBI Vaccines (NASDAQ:<a href="https://investorplace.com/stock-quotes/vbiv-stock-quote/">VBIV</a>) shares are dropping more than 34% <a href="https://investorplace.com/2024/08/why-is-vbi-vaccines-vbiv-stock-up-62-today/">after a rally yesterday</a>.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) stock is decreasing over 28% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500633&amp;type=PDF&amp;symbol=XPON&amp;cdn=cc4a67ceca06cec716b8eaa852fb2069&amp;companyName=Expion360+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-06">with a public offering</a>.</li>



<li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are falling more than 22% <a href="https://www.investing.com/news/stock-market-news/evotec-shares-crash-36-on-profit-warning-3558654">on a profit warning</a>.</li>



<li>CryoPort (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyrx-stock-quote/">CYRX</a>) stock closes out our pre-market stock movers down over 20% after <a href="https://finance.yahoo.com/news/cryoport-inc-cyrx-reports-q2-230011376.html">missing Q2 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is falling on Wednesday after the company provided investors with an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">update on its restructuring plans</a>.



Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.



Talis Biomedical notes that this special committee will focus on a few troublesome matters for the company. That includes ongoing securities class action litigation, determining if the company should file for Chapter 11 bankruptcy and settling any claims made against current or former company leaders in a potential bankruptcy filing.



Talis Biomedical notes that it specifically brought in Ferrari and Young as board members due to their deep experience in bankruptcy and liquidation proceedings. At the same time that they join the board, Heinrich Dreismann has voluntarily resigned from it.



<h2>What This Means for TLIS Stock</h2>



Considering the focus on bankruptcy talk today, it makes sense that investors are spooked. A bankruptcy and liquidation would spell the end of the company and TLIS stock.



With this news comes some 18,000 shares of TLIS stock changing hands. This may not seem like much but it&rsquo;s more than double the company&rsquo;s daily average trading volume.



TLIS stock is down 51.5% this morning.



Investors will want to keep reading for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market available today! That includes what&rsquo;s happening with shares of Scorpius&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock, G1 Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) stock and Zhongchao&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock today. All of this info is ready at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-scorpius-scpx-stock-down-79-today/">Why Is Scorpius (SCPX) Stock Down 79% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-g1-therapeutics-gthx-stock-up-66-today/">Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-zhongchao-zcmd-stock-up-52-today/">Why Is Zhongchao (ZCMD) Stock Up 52% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-talis-biomedical-tlis-stock-down-52-today/">Why Is Talis Biomedical (TLIS) Stock Down 52% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the second quarter of 2024.<ul><li>Talis Biomedical reported earnings per share of -$4.86.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tlis-stock-earnings-talis-biomedical-for-q2-of-2024/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024

Greenlight adds new position in CNH Industrial, boosts Peloton, others in Q3

ALIT

ATMVR

BHFAL

BHFAM

BHFAN

BHFAO

BHFAP

CEIX

CYRX

DNMR

DZSI

EVAV

FCNCA

FCNCB

FCNCO

FCNCP

GLRE

GPOR

GRBK

INGN

LBTYA

LIVN

LUMN

NPWR

NVRO

NYCB

PENN

PTON

SCPX

SHOP

TCKRF

TECK

VBIV

VCYT

WFRD

WFTUF

ZCMD

Legal

Press Releases

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Short Sellers

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

RENT

TASK

BTIG

B of A Securities

Comments

Talis Biomedical

Talis Biomedical (TLIS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga